Regeneron Faces Securities Class Action Over Failed Melanoma Trial

The complaint alleges that Regeneron concealed fundamental flaws in the study’s statistical assumptions and failed to report that the treatment arm lacked meaningful clinical differentiation from standard therapies. According to the filing, these omissions artificially inflated the company's stock price while the trial faced an increasing risk of missing its primary endpoint.

Financial fallout from these disclosures occurred in two distinct stages. On April 29, 2026, after the company revealed modifications to patient eligibility for progression-free survival analysis, the stock price dropped 6.2%. A sharper decline followed on May 18, 2026, when shares fell 9.8% after the company confirmed the trial had failed to reach statistical significance. Shareholders who suffered losses during the class period have until September 14, 2026, to seek appointment as lead plaintiff in the case. Robbins LLP is handling the matter on a contingency fee basis, meaning investors do not incur out-of-pocket costs for participation.